Bariatric surgery, on the evidence outside trials. A review synthesizing real-world results across lifestyle programs, weight medications, surgery and endoscopic procedures puts surgery first for size and durability. It also remains substantially underused, with racial, socioeconomic and insurance disparities.
Incretin drugs produce large trial results and smaller real-world effectiveness. The review names five reasons for that gap. Cost is one of them, not the whole of it. Intensive lifestyle programs reach about 5%, and regain is common once the program ends.
This site sells against that ranking, so it is worth stating plainly. On cardiovascular outcomes surgery beat semaglutide too, at 4.4% against 6.6% [2]. On three-year spending the two came out level, with the drug shifting who pays rather than what is spent [3]. What a drug buys instead is reversibility, no operation, and a different distribution of who pays.
Somebody deciding what to do about their weight is choosing between four or five approaches. Almost every source they read is selling one of them. Including, to be plain about it, the market this site covers. This review is not, and its ordering is not the one a website would produce.
What it covers
A narrative synthesis of real-world evidence, searched through July 2026. It covers adherence, persistence, discontinuation, tolerability, access and patient satisfaction. The treatments are intensive lifestyle programs, pharmacotherapy including the incretin drugs, metabolic bariatric surgery, and endoscopic procedures. [1] Randomized trials are used to give context to what happens in practice rather than to stand in for it.
Where the drugs actually land
Incretin-based therapies produce substantial weight loss in trials and relatively smaller effectiveness in practice. The review names five reasons. People not starting at all. Incomplete dose escalation. Gastrointestinal side effects. Treatment interruptions. Financial or insurance barriers.
That list is worth reading slowly, because four of the five have nothing to do with price. This site’s own coverage keeps arriving at the same place. In a clinic program where the drug was free, median persistence was still under eleven months. A cheaper seller solves one of five problems.
The other options, briefly
Intensive lifestyle programs generally achieve about 5% weight loss, with attrition during and regain after. Older weight medications show poor persistence driven by neurologic, psychiatric or gastrointestinal intolerance, despite some of them costing far less.
Endoscopic sleeve gastroplasty produces moderate, durable weight loss with low rates of serious adverse events. Intragastric balloons are more limited — by intolerance, by the need for reintervention, and by regain after removal.
What this changes about a purchase
It reframes the question from “which seller” to “which treatment”, and most people arrive at this market having skipped that step. A telehealth intake form is not where surgery gets discussed. A price comparison cannot tell you that the most durable option in the literature is one you have not been offered.
None of which makes buying a GLP-1 wrong. It makes it a choice among several, with real trade-offs on cost, durability, invasiveness and access. Once that choice is made, this site's arithmetic applies. what a GLP-1 actually costs and what six months of it comes to are the right questions then. They are the wrong ones before.
The review concludes that real-world effectiveness turns on more than biological efficacy. Tolerability, adherence, access and sustained support decide it. Three of those four are things a website cannot supply, which is worth knowing before weighing the money against the outcome.